Xiaoyun Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiaoyun Zhang has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Xiaodong Cui
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Shandong Second Medical University, Weifang, PR China
4 shared publications - Hao Chen
Department of Physiology, School of Basic Medical Sciences, Shandong Second Medical University, Weifang, China
2 shared publications Jie Ju
Department of Physiology, School of Basic Medical Sciences, Shandong Second Medical University, Weifang, Shandong, PR China
2 shared publicationsJie Li
Department of Physiology & Pathophysiology, School of Basic Medical Sciences, Shandong Second Medical University, Weifang, Shandong, PR China
2 shared publicationsMin Cheng
Weifang Key Laboratory of Basic Research on Chronic Diseases and Stem Cell Therapy, School of Basic Medical Sciences, Shandong Second Medical University, Weifang, Shandong, PR China
2 shared publicationsMin Liu
Department of neurology, Sunshine Union Hospital, Weifang, Shandong, PR China
2 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 10 March 2026
- Published by Springer Nature in Cell Death Discovery
- Vol. 12 (1)
Oscillatory shear stress-driven endothelial-to-mesenchymal transition: a critical mechanical signal transduction mechanism in atherosclerosis progression
Atherosclerosis constitutes the primary pathological basis for cardiovascular diseases. It most commonly develops at the branching and curved regions of blood vessels. The disturbed blood flow in these regions can generate oscillatory shear stress (OSS). Endothelial cells exposed to OSS progressively undergo a transformation into mesenchymal cells, a process known as endothelial-to-mesenchymal transition (EndMT). EndMT is a critical event in the development of atherosclerosis. OSS promotes the occurrence of EndMT through multiple pathways. This paper provides a comprehensive analysis of the phenomena and mechanisms of OSS-induced EndMT, offering theoretical insights into the pathogenic mechanisms of atherosclerosis and corresponding therapeutic strategies.
- 10 March 2026
- Published by Springer Nature in Cell Death Discovery
- Vol. 12 (1)
Top Cited PapersOpen AccessOscillatory shear stress-driven endothelial-to-mesenchymal transition: a critical mechanical signal transduction mechanism in atherosclerosis progression
Atherosclerosis constitutes the primary pathological basis for cardiovascular diseases. It most commonly develops at the branching and curved regions of blood vessels. The disturbed blood flow in these regions can generate oscillatory shear stress (OSS). Endothelial cells exposed to OSS progressively undergo a transformation into mesenchymal cells, a process known as endothelial-to-mesenchymal transition (EndMT). EndMT is a critical event in the development of atherosclerosis. OSS promotes the occurrence of EndMT through multiple pathways. This paper provides a comprehensive analysis of the phenomena and mechanisms of OSS-induced EndMT, offering theoretical insights into the pathogenic mechanisms of atherosclerosis and corresponding therapeutic strategies.
- Open Access
- 10 December 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 12 (1)
The beta1-adrenergic receptor in the heart
Beta1-adrenergic receptor (β 1 -AR) belongs to G protein-coupled receptors, regulating cardiac physiological and pathological process through complex signaling pathways. Physiologically, the activation of β 1 -AR produces positive chronotropic, positive inotropic and positive dromotropic effects in the heart. However, excessive or sustained activation of β 1 -AR can cause myocardial injury, arrhythmias, and heart failure. The β 1 -AR in the heart exhibits tissue-specific distribution patterns and subcellular localization features adapted to its function within cardiomyocytes. Upon ligand binding, the β 1 -AR undergoes conformational changes and transmits signaling through G protein-dependent pathways (β 1 -AR/Gs and β 1 -AR/Gi) as well as a G protein-independent pathway (β 1 -AR/β-arrestin) to regulate cardiac activity. Subsequently, the β 1 -AR can either dissociate from G protein to undergo desensitization and terminate signal transduction, or it can be endocytosed into the cell, transported to the lysosome to be degraded, or returned to the plasma membrane to continue its function. Additionally, it has been found that β 1 -AR can cause or exacerbate heart disease when abnormal changes occur in its distribution density, localization, and mediated downstream signaling pathways. Therefore, β 1 -AR represents an important pharmacotherapeutic target for the treatment of cardiac diseases. Among the relevant therapeutic agents, β 1 -AR blockers designed specifically against β 1 -AR have evolved to the third generation. This review comprehensively analyzes β 1 -AR from perspectives including its research history, expression, and distribution in the heart, protein structure, signaling pathways, and associations with cardiac diseases.
- 10 December 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 12 (1)
Open AccessThe beta1-adrenergic receptor in the heart
Beta1-adrenergic receptor (β 1 -AR) belongs to G protein-coupled receptors, regulating cardiac physiological and pathological process through complex signaling pathways. Physiologically, the activation of β 1 -AR produces positive chronotropic, positive inotropic and positive dromotropic effects in the heart. However, excessive or sustained activation of β 1 -AR can cause myocardial injury, arrhythmias, and heart failure. The β 1 -AR in the heart exhibits tissue-specific distribution patterns and subcellular localization features adapted to its function within cardiomyocytes. Upon ligand binding, the β 1 -AR undergoes conformational changes and transmits signaling through G protein-dependent pathways (β 1 -AR/Gs and β 1 -AR/Gi) as well as a G protein-independent pathway (β 1 -AR/β-arrestin) to regulate cardiac activity. Subsequently, the β 1 -AR can either dissociate from G protein to undergo desensitization and terminate signal transduction, or it can be endocytosed into the cell, transported to the lysosome to be degraded, or returned to the plasma membrane to continue its function. Additionally, it has been found that β 1 -AR can cause or exacerbate heart disease when abnormal changes occur in its distribution density, localization, and mediated downstream signaling pathways. Therefore, β 1 -AR represents an important pharmacotherapeutic target for the treatment of cardiac diseases. Among the relevant therapeutic agents, β 1 -AR blockers designed specifically against β 1 -AR have evolved to the third generation. This review comprehensively analyzes β 1 -AR from perspectives including its research history, expression, and distribution in the heart, protein structure, signaling pathways, and associations with cardiac diseases.
- Open Access
- 24 September 2025
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 30 (9) , 36475
The Role of m6A Modification in Regulating MSC Differentiation and Immunomodulation: Implications for Regenerative Medicine and Therapeutic Applications
Mesenchymal stem cells (MSCs) are widely utilized in tissue repair, anti-inflammatory treatment, and cell therapy due to their remarkable multidirectional differentiation potential, immunosuppressive capabilities, and low immunogenicity. However, the regulatory mechanisms underlying their functions are intricate, and epigenetic modifications are a significant contributing factor. N6-methyladenosine (m6A) modification affects the proliferation, differentiation, and immunomodulation of MSCs by regulating the stability, transport, and translation of RNA. Studies have shown that m6A modification promotes osteogenic differentiation through the bone morphogehetic protein/small mothers against decapentaplegic (BMP/Smad) and wingless-related integration site/β-catenin (Wnt/β-catenin) pathways. It also enhances the anti-inflammatory effect of MSCs by modulating immune cell polarization and the release of inflammatory mediators. Moreover, exosomes secreted by MSCs contribute to immunomodulation and the response to cancer treatment by regulating the m6A modification of genes in target cells. “Writers” of m6A, such as methyltransferase-like 3 (METTL3) and METTL14, and “erasers”, such as fat mass and obesity-associated protein (FTO) and alkB homolog 5 (ALKBH5), are crucial in regulating the functions of MSCs. Targeting m6A modification via the clinical application of MSCs may represent a new cancer treatment strategy. Therefore, a comprehensive investigation of the m6A regulatory mechanism is essential. This review provides theoretical and technical support for the clinical use of MSCs, facilitating the development of more effective therapeutic strategies.
- 24 September 2025
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 30 (9) , 36475
Open AccessThe Role of m6A Modification in Regulating MSC Differentiation and Immunomodulation: Implications for Regenerative Medicine and Therapeutic Applications
Mesenchymal stem cells (MSCs) are widely utilized in tissue repair, anti-inflammatory treatment, and cell therapy due to their remarkable multidirectional differentiation potential, immunosuppressive capabilities, and low immunogenicity. However, the regulatory mechanisms underlying their functions are intricate, and epigenetic modifications are a significant contributing factor. N6-methyladenosine (m6A) modification affects the proliferation, differentiation, and immunomodulation of MSCs by regulating the stability, transport, and translation of RNA. Studies have shown that m6A modification promotes osteogenic differentiation through the bone morphogehetic protein/small mothers against decapentaplegic (BMP/Smad) and wingless-related integration site/β-catenin (Wnt/β-catenin) pathways. It also enhances the anti-inflammatory effect of MSCs by modulating immune cell polarization and the release of inflammatory mediators. Moreover, exosomes secreted by MSCs contribute to immunomodulation and the response to cancer treatment by regulating the m6A modification of genes in target cells. “Writers” of m6A, such as methyltransferase-like 3 (METTL3) and METTL14, and “erasers”, such as fat mass and obesity-associated protein (FTO) and alkB homolog 5 (ALKBH5), are crucial in regulating the functions of MSCs. Targeting m6A modification via the clinical application of MSCs may represent a new cancer treatment strategy. Therefore, a comprehensive investigation of the m6A regulatory mechanism is essential. This review provides theoretical and technical support for the clinical use of MSCs, facilitating the development of more effective therapeutic strategies.
- 2 September 2021
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 22 (12) , 1548-1558
Advances in the Occurrence of Pyroptosis: A Novel Role in Atherosclerosis
Pyroptosis is a new type of pro-inflammatory programmed cell death identified over the last few years and has since attracted researchers' attention. Current research demonstrates that pyroptosis's primary process is dependent on caspase-1 protein and gasdermin D protein and is accompanied by the release of inflammatory substances. However, the specific mechanisms and physiological or pathophysiological processes involved in pyroptosis are unclear. Presently, research on the occurrence, development, and treatment of various diseases associated with pyroptosis is of significant value. Pyroptosis has been implicated in the pathogenesis of atherosclerosis. For instance, numerous studies have revealed that pyroptosis is involved in the development and progression of atherosclerosis, and it is closely associated with pyroptosis of three essential cells (vascular endothelial cells, macrophages, and vascular smooth muscle cells) in atherosclerosis. The advancement of research on pyroptosis is anticipated to give insights into its application as a potential method for treating diseases. This article mainly reviews the relationship between pyroptosis and associated mechanisms factors that cause pyroptosis and the relationship between pyroptosis and various diseases, especially atherosclerosis.
- 2 September 2021
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 22 (12) , 1548-1558
Advances in the Occurrence of Pyroptosis: A Novel Role in Atherosclerosis
Pyroptosis is a new type of pro-inflammatory programmed cell death identified over the last few years and has since attracted researchers' attention. Current research demonstrates that pyroptosis's primary process is dependent on caspase-1 protein and gasdermin D protein and is accompanied by the release of inflammatory substances. However, the specific mechanisms and physiological or pathophysiological processes involved in pyroptosis are unclear. Presently, research on the occurrence, development, and treatment of various diseases associated with pyroptosis is of significant value. Pyroptosis has been implicated in the pathogenesis of atherosclerosis. For instance, numerous studies have revealed that pyroptosis is involved in the development and progression of atherosclerosis, and it is closely associated with pyroptosis of three essential cells (vascular endothelial cells, macrophages, and vascular smooth muscle cells) in atherosclerosis. The advancement of research on pyroptosis is anticipated to give insights into its application as a potential method for treating diseases. This article mainly reviews the relationship between pyroptosis and associated mechanisms factors that cause pyroptosis and the relationship between pyroptosis and various diseases, especially atherosclerosis.